Phibro Animal Health Corporation $PAHC Shares Bought by Lazard Asset Management LLC

Lazard Asset Management LLC increased its holdings in Phibro Animal Health Corporation (NASDAQ:PAHC) by 11.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 145,811 shares of the company’s stock after purchasing an additional 14,944 shares during the quarter. Lazard Asset Management LLC’s holdings in Phibro Animal Health were worth $8,065,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Castleark Management LLC acquired a new position in shares of Phibro Animal Health in the 1st quarter worth $7,904,000. Renaissance Technologies LLC lifted its stake in Phibro Animal Health by 5.8% during the first quarter. Renaissance Technologies LLC now owns 576,735 shares of the company’s stock valued at $31,899,000 after buying an additional 31,435 shares in the last quarter. Sei Investments Co. boosted its holdings in shares of Phibro Animal Health by 15.7% in the first quarter. Sei Investments Co. now owns 156,948 shares of the company’s stock worth $8,681,000 after buying an additional 21,339 shares during the period. Cetera Investment Advisers increased its position in shares of Phibro Animal Health by 2.7% in the first quarter. Cetera Investment Advisers now owns 10,997 shares of the company’s stock worth $608,000 after acquiring an additional 293 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Phibro Animal Health by 3.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 507,852 shares of the company’s stock valued at $28,086,000 after purchasing an additional 15,517 shares during the period. 99.34% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Jack Bendheim sold 4,528 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $48.49, for a total value of $219,562.72. Following the completion of the sale, the chief executive officer directly owned 56,152 shares in the company, valued at approximately $2,722,810.48. The trade was a 7.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 50.13% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on PAHC. Wall Street Zen downgraded Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Zacks Research lowered shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 21st. Weiss Ratings downgraded shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, June 15th. Finally, Citigroup cut their target price on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a research report on Thursday, May 14th. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Phibro Animal Health presently has a consensus rating of “Hold” and an average target price of $42.50.

Phibro Animal Health Stock Down 1.4%

PAHC stock opened at $36.45 on Friday. The firm has a market cap of $1.48 billion, a PE ratio of 15.64, a PEG ratio of 0.52 and a beta of 0.46. Phibro Animal Health Corporation has a 1 year low of $25.58 and a 1 year high of $60.08. The company has a fifty day simple moving average of $32.65 and a 200 day simple moving average of $43.20. The company has a current ratio of 3.17, a quick ratio of 1.26 and a debt-to-equity ratio of 1.97.

Phibro Animal Health (NASDAQ:PAHC) last posted its earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.04. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%.The company had revenue of $383.54 million for the quarter, compared to analyst estimates of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. Sell-side analysts anticipate that Phibro Animal Health Corporation will post 3.08 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Investors of record on Wednesday, September 2nd will be paid a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date of this dividend is Wednesday, September 2nd. Phibro Animal Health’s dividend payout ratio (DPR) is presently 20.60%.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.